Skip to main content
. 2016 Nov 11;187(1):174–184. doi: 10.1111/cei.12838

Figure 7.

Figure 7

MicroRNA‐26a (Mir‐26a)–IL‐17 axis attenuates non‐alcoholic fatty liver disease (NAFLD) though inhibition of interleukin (IL)−6. (a) Indicating total liver weight after 20 weeks of high‐fat diet (HFD) feeding; (b) indicating hepatic triglyceride levels after 20 weeks of HFD feeding; (c) indicating serum alanine transaminase (ALT) levels after 20 weeks of HFD feeding; (d) luciferase activity assay of HEk293 cells at 36 h after co‐transfection with Mir‐26a and pGLO‐IL‐6‐3′ UTR or pGLO‐IL‐6‐3′ UTR mutant; (e) indicating IL‐17 mRNA level in liver after 20 weeks of HFD feeding; (f) indicating IL‐17 protein level in liver after 20 weeks of HFD feeding; (g) indicating total liver weight after 20 weeks of HFD feeding; (h) indicating hepatic triglyceride levels after 20 weeks of HFD feeding; (i) indicating serum ALT levels after 20 weeks of HFD feeding. *P < 0·01; n = 6.